Literature DB >> 18024528

Screening using serum percentage of carbohydrate-deficient transferrin for congenital disorders of glycosylation in children with suspected metabolic disease.

Celia Pérez-Cerdá1, Dulce Quelhas, Ana I Vega, Jesús Ecay, Laura Vilarinho, Magdalena Ugarte.   

Abstract

BACKGROUND: Diagnoses of congenital disorders of glycosylation (CDG) are based on clinical suspicion and analysis of transferrin (Tf) isoforms. Here we present our experience of CDG screening in children with a suspected metabolic disease by determination of serum percentage of carbohydrate-deficient transferrin (%CDT) in tandem with isoelectric focusing (IEF) analysis of Tf and alpha(1)-antitrypsin (alpha(1)-AT).
METHODS: We performed approximately 8000 serum %CDT determinations using %CDT turbidimetric immunoassay (TIA). In selected samples, IEF analysis of Tf and alpha(1)-AT was carried out on an agarose gel (pH 4-8) using an electrophoresis unit. The isoforms were detected by Western blotting and visualized by color development. We performed neuraminidase digestion of serum to detect polymorphic variants of Tf.
RESULTS: We established a cutoff value for serum %CDT of 2.5% in our pediatric population. Sixty-five patients showed consistently high values of serum %CDT. In accordance with Tf and alpha(1)-AT IEF profiles, enzyme assays, and mutation analysis, we made the following diagnoses: 23 CDG-Ia, 1 CDG-Ib, and 1 conserved oligomeric Golgi 1 (COG-1) deficiency. In addition, we identified 13 CDG-Ix non Ia, non-Ib; 3 CDG-Ix; and 9 CDG-IIx cases, albeit requiring further characterization; 9 patients with a secondary cause of hypoglycosylation and 6 with a polymorphic Tf variant were also detected.
CONCLUSION: The combined use of CDT immunoassay with IEF of Tf and alpha(1)-AT is a useful 1st-line screening tool for identifying CDG patients with an N-glycosylation defect. Additional molecular investigations must of course be carried out to determine the specific genetic disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024528     DOI: 10.1373/clinchem.2007.093450

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  Neurology of inherited glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

2.  The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations.

Authors:  B Pérez; P Briones; D Quelhas; R Artuch; A I Vega; E Quintana; L Gort; M J Ecay; G Matthijs; M Ugarte; C Pérez-Cerdá
Journal:  JIMD Rep       Date:  2011-06-22

3.  Toward an automatic tool for oligoclonal band detection in cerebrospinal fluid and tears for multiple sclerosis diagnosis: lane segmentation based on a ribbon univariate open active contour.

Authors:  Farah Haddad; Samuel Boudet; Laurent Peyrodie; Nicolas Vandenbroucke; Patrick Hautecoeur; Gérard Forzy
Journal:  Med Biol Eng Comput       Date:  2020-02-24       Impact factor: 2.602

4.  A novel congenital disorder of glycosylation type without central nervous system involvement caused by mutations in the phosphoglucomutase 1 gene.

Authors:  Belén Pérez; Celia Medrano; Maria Jesus Ecay; Pedro Ruiz-Sala; Mercedes Martínez-Pardo; Magdalena Ugarte; Celia Pérez-Cerdá
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

5.  Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1.

Authors:  Sarah Finlayson; Jacqueline Palace; Katsiaryna Belaya; Timothy J Walls; Fiona Norwood; Georgina Burke; Janice L Holton; Samuel I Pascual-Pascual; Judith Cossins; David Beeson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-02-27       Impact factor: 10.154

6.  Ratiometric Raman spectroscopy for quantification of protein oxidative damage.

Authors:  Dongmao Zhang; Dongping Jiang; Michael Yanney; Sige Zou; Andrzej Sygula
Journal:  Anal Biochem       Date:  2009-05-18       Impact factor: 3.365

Review 7.  CDG Therapies: From Bench to Bedside.

Authors:  Sandra Brasil; Carlota Pascoal; Rita Francisco; Dorinda Marques-da-Silva; Giuseppina Andreotti; Paula A Videira; Eva Morava; Jaak Jaeken; Vanessa Dos Reis Ferreira
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.